PRFX
PainReform Ltd. [PRFX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
PRFX Stock Summary
Top 10 Correlated ETFs
PRFX
Top 10 Correlated Stocks
PRFX
In the News
PRFX Financial details
Company Rating
-
Market Cap
1.9M
Income
-9.23M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
7
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-0.47
Forward P/E
-
PEG
0.54
P/S
51.79
P/B
0.4
P/C
-
P/FCF
-0.56
Quick Ratio
7.84
Current Ratio
9.81
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-7.54
EPS next Y
-
EPS next Q
-
EPS this Y
-13.45%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-10675.76%
-
-
-
-
SMA20
-33.33%
SMA50
-33.33%
SMA100
-33.33%
Inst Own
-
Inst Trans
-
ROA
-69%
ROE
-84%
ROC
-0.95%
Gross Margin
100%
Oper. Margin
-10786%
Profit Margin
-8706%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.417-26.41
52W High
-
52W Low
-
RSI
42
Rel Volume
1.24
Avg Volume
126.91K
Volume
157.57K
Perf Week
0.72%
Perf Month
-29.12%
Perf Quarter
-28.89%
Perf Half Y
-9.66%
-
-
-
-
Beta
0.528
-
-
Volatility
0.14%, 0.39%
Prev Close
1.2%
Price
2.105
Change
-3.88%
Company Profile
- Volume Average 126.91K
- Market Capitalization 1.9M
- Employee 7
- CEO Mr. Ilan Hadar M.B.A.
- Headquarters Tel Aviv,IL
- IPO Date 2020-09-01
-
Website
https://www.painreform.com 
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
